Category Archives: Uncategorized

Protox reports 2008 third quarter results

Protox Therapeutics

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today released third quarter 2008 financial results for the three months ended September 30, 2008 (“2008 Q3”).

“The third quarter marked significant advances for Protox, most prominently the early completion of patient enrolment in our Phase 2a study of PRX302 for the treatment of BPH,” said Dr. Fahar Merchant, President and CEO of Protox. “We are very pleased with the 12 month data that we recently announced from our Phase 1 BPH study and look forward to releasing top line results from our Phase 2a BPH study before the end of the year.”

Illumina Selects GenoLogics as Next Generation Sequencing Lab & Data Management Partner

GenoLogics today announced that Geneus, their lab and data management system for genomics, was selected by Illumina to provide a combined solution […]

Carmanah Q3 2008 Delivers Sustained Growth and Profitability

Carmanah Technologies

Carmanah Technologies Corporation (TSX:CMH) today announces its third quarter financial results for the three-month period ending September 2008.

In Q3 2008, Carmanah’s recent strategic renewal and restructuring initiative proved especially timely, as the newly streamlined Company navigated challenging global market conditions to deliver its third profitable EBITDA quarter (adjusted for restructuring charge) in a row. While supporting the restructuring initiatives announced in June, the Company introduced a new flagship product to its line of solar LED marine lanterns, entered into a partnership with wireless technology provider ENCOM, and reported significant sales wins in key target markets including aviation lights for airfields in the Middle East and solar power systems for telecommunication towers throughout North Africa.

Two Out Of Three Florida Top Principals Use Victoria-based Etraffic's SnapShot Data Analysis Tool for School Improvement

Etraffic Solutions

The finalists for the 6th Annual Leonard Miller Principal Leadership Award, hosted by the Council for Educational Change, were announced on October 31st, 2008. Two of the three finalists actively use Etraffic’s Student Performance SnapShot data analysis tool to help raise student achievement levels.

The finalists were chosen from state-wide applicants in Florida who demonstrated extraordinary leadership in a Council program(s) in these three criteria: raised student achievement; empowered staff leadership; and formed meaningful partnerships.

Dr. Rosann Sidener from Miami-Dade Public Schools raised Miami Beach High’s school grade from a D to a B. Terry Strong, Winston EL, Polk County Schools raised the school grade from C to B to A, with 81% of the student population on free and reduced lunch programs. Both utilize the SnapShot data analysis tool.

Vigil Health Solutions Reports Second Quarter Results

November 10, 2008 (Victoria) – Vigil Health Solutions Inc. (“Vigil”) announces the results of operations for the quarter ending September 30, 2008. […]

GenoLogics Signs Global Agreement with Pfizer

Victoria, BC, Canada – November 10, 2008 – GenoLogics, the leader in translational research informatics solutions for life sciences, today announced that […]

GenoLogics Signs Global Agreement with Pfizer to provide Informatics Solutions to Multiple Research Centers

GenoLogics signs agreement with Pfizer

GenoLogics, the leader in translational research informatics solutions for life sciences, today announced that it has signed a three year global agreement with Pfizer to provide informatics solutions to its research labs.

Under the terms of the agreement, GenoLogics will provide an enterprise enabled lab and data management system to capture, contextualize and integrate science data in multiple locations world wide. In addition to the ability to leverage data standards across labs by virtue of a common informatics platform, GenoLogics will provide Pfizer with the tools to enable web-based collaboration, bioinformatics pipelining, auditability and reporting of cross-science data.

Zymeworks Appoints Noel Hall to Its Board of Directors

Zymeworks appoints Hall

Zymeworks Inc., a privately held computational biotechnology company, today announced the appointment of Noel Hall to its board of directors. Mr. Hall’s extensive knowledge of the biotechnology industry, along with his business-building experience, will significantly contribute to Zymeworks’ growth by guiding the development of its therapeutics pipeline.

Noel Hall is a consultant to the life sciences industry with over 25 years of experience in the biotechnology sector. He was the Co-founder, President, and Director of Aspreva Pharmaceuticals, which was acquired by the Galenica Group in January 2008. Prior to Aspreva, Mr. Hall co-founded the life sciences practice of consulting firm Hill and Knowlton and served as Head of Global Strategic Planning for the firm’s worldwide pharmaceutical consulting practice.

CANTEST welcomes new Vice President of Operations

Burnaby, British Columbia – CANTEST is pleased to announce the appointment of Dr. Curtis Braun as Vice President of Operations.       In […]

Zymeworks Appoints Noel Hall to Its Board of Directors

Zymeworks Inc., a privately held computational biotechnology company, today announced the appointment of Noel Hall to its board of directors. Mr. Hall’s […]